DateJanuary 31, 2022
Learn more about Invicro and Ambry—the history, values, and contributions advancing health care worldwide
Introduction to Invicro
Headquartered in Needham, Massachusetts, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all imaging modalities, stages of the drug development pipeline (Phase 0-IV) and therapeutic areas—including neurology, oncology and systemic and rare diseases.
With over 430 employees, including 60 M.D.s and Ph.D.s, Invicro operates out of eight global laboratories, clinics and sites within the United States in Massachusetts, Michigan, California and globally in the United Kingdom, India and Japan. Invicro has performed more than 3,200 research trials and processed over 40,000,000 (DIACOM) Images. They are backed by 2,000+ qualified imaging centers worldwide.
Invicro’s quantitative biomarker services, advanced analytics and AI (Artificial Intelligence) tools and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant® and iPACS®, and their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
Invicro solves drug development problems and provides answers to questions that support more timely and accurate decision-making throughout the development process using a platform that harnesses the unique depth and breadth of our expertise in science, medicine, imaging, operations, analytics, and software. The Invicro platform provides high-quality Design, Capture, Analysis and Management of data across the drug development pipeline.
Design
Our experts and agnostic technology give us the ability to better design customized studies. With the support of a strong team of Ph.D.s and M.D.s, Invicro’s scientists utilize powerful open-architected technology to better customize studies based on sponsors’ specific questions.
Capture
Our broad range of available modalities are managed by expert scientists to ensure delivery of high-quality, consistent and quantifiable data from both imaging and non-imaging sources to meet the needs of the study design.
Analyze
Invicro’s world-class analytics team, aided by state-of-the-art software including VivoQuant®, MIAKAT™ and IQ-Analytics, delivers advanced domain knowledge and machine learning for deeper understanding and insight.
Manage
The integration of our VivoQuant® and iPACS® management software provides an unsurpassed collaborative experience in end-to-end data management, from discovery to Phase IV clinical trials.
Invicro believes its services and software, and most importantly, its people, are an integral part of the solutions that advance important medical innovations to treat disease and improve drug discovery.
Invicro upholds six core values: passionate, open & honest, innovative, inclusive & collaborative, accountable, and customer centric. These guide their team and individual contributions in every part of their work. Each core value brings structure to Invicro’s corporate principles and complements the internal controls they have in place to ensure the highest degree of integrity.
Introduction to Ambry Genetics
Founded in 1999, Ambry Genetics is headquartered in Aliso Viejo, California and has over 850 employees. Ambry provides health care providers with accurate, affordable, and medically actionable genomic information, so they can make informed medical management decisions with their patients.
At Ambry, our comprehensive genetic testing menu includes screening and diagnosis for myriad conditions, including hereditary cancers, cardiovascular diseases, neurodevelopmental disorders, epilepsy, rare diseases, and exome. Our 58,000 square foot “SuperLab” is CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified. We have conducted more than 1.5 million genetic tests to date (excluding COVID testing). Our flagship hereditary cancer panel, CancerNext®, includes 36 genes linked to an increased lifetime risk for one or more cancers such as breast, colorectal, ovarian, uterine and others.
Ambry has a strong history of firsts in the industry:
- first to offer full-gene sequencing of CFTR in 2001 and clinical exome sequencing services in 2011,
- first to offer BRCA-related testing following the Supreme Court ruling in 2013, and
- first to offer paired DNA/RNA genetic testing for hereditary cancer in 2019.
Ambry has over 100 genetic counselors and other medical experts with clinical genomic experience. Ambry’s translational scientists are also heavily involved in research collaborations and have over 400 peer-reviewed publications and nearly 450 studies presented at national and international conferences.
Ambry also offers the CARE (Comprehensive Assessment Risk and Education) Program™. CARE identifies patients at increased risk for diseases—earlier. Developed to provide physicians and patients with genetic insights and support, we’re making it easy to guide medical management and make personalized treatment decisions. CARE streamlines screening, provides education on genetic testing and links test ordering and results together in one online platform.
Ambry has six main company values:
- Be real. We believe our authenticity enables us to work together with trust and transparency.
- We care. We recognize that behind each sample, there is a person looking for an answer.
- We evolve. Whether it’s our products, technology, or even ourselves, Ambry believes in new and inventive ideas that advance us as a company and individuals.
- We’re motivated. Every day, we acknowledge that the work we do is meaningful and motivates us to carry forward with our best.
- One Ambry. We value the knowledge and skills of all contributors as we face down challenges and celebrate successes.
- We say, we do. We hold ourselves to a high standard and know our responsibilities.
Our embodiment of these values throughout the organization has resulted in several industry awards voted for by company employees. We were included among Orange County Top Workplaces and Comparably’s Best Company Culture, Best Company for Women, Best Company Leadership and Best Company Outlook.
Learn more about Invicro and Ambry—the history, values, and contributions advancing health care worldwide
Introduction to Invicro
Headquartered in Needham, Massachusetts, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all imaging modalities, stages of the drug development pipeline (Phase 0-IV) and therapeutic areas—including neurology, oncology and systemic and rare diseases.
With over 430 employees, including 60 M.D.s and Ph.D.s, Invicro operates out of eight global laboratories, clinics and sites within the United States in Massachusetts, Michigan, California and globally in the United Kingdom, India and Japan. Invicro has performed more than 3,200 research trials and processed over 40,000,000 (DIACOM) Images. They are backed by 2,000+ qualified imaging centers worldwide.
Invicro’s quantitative biomarker services, advanced analytics and AI (Artificial Intelligence) tools and clinical operational services are backed by their industry-leading software informatics platforms, VivoQuant® and iPACS®, and their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
Invicro solves drug development problems and provides answers to questions that support more timely and accurate decision-making throughout the development process using a platform that harnesses the unique depth and breadth of our expertise in science, medicine, imaging, operations, analytics, and software. The Invicro platform provides high-quality Design, Capture, Analysis and Management of data across the drug development pipeline.
Design
Our experts and agnostic technology give us the ability to better design customized studies. With the support of a strong team of Ph.D.s and M.D.s, Invicro’s scientists utilize powerful open-architected technology to better customize studies based on sponsors’ specific questions.
Capture
Our broad range of available modalities are managed by expert scientists to ensure delivery of high-quality, consistent and quantifiable data from both imaging and non-imaging sources to meet the needs of the study design.
Analyze
Invicro’s world-class analytics team, aided by state-of-the-art software including VivoQuant®, MIAKAT™ and IQ-Analytics, delivers advanced domain knowledge and machine learning for deeper understanding and insight.
Manage
The integration of our VivoQuant® and iPACS® management software provides an unsurpassed collaborative experience in end-to-end data management, from discovery to Phase IV clinical trials.
Invicro believes its services and software, and most importantly, its people, are an integral part of the solutions that advance important medical innovations to treat disease and improve drug discovery.
Invicro upholds six core values: passionate, open & honest, innovative, inclusive & collaborative, accountable, and customer centric. These guide their team and individual contributions in every part of their work. Each core value brings structure to Invicro’s corporate principles and complements the internal controls they have in place to ensure the highest degree of integrity.
Introduction to Ambry Genetics
Founded in 1999, Ambry Genetics is headquartered in Aliso Viejo, California and has over 850 employees. Ambry provides health care providers with accurate, affordable, and medically actionable genomic information, so they can make informed medical management decisions with their patients.
At Ambry, our comprehensive genetic testing menu includes screening and diagnosis for myriad conditions, including hereditary cancers, cardiovascular diseases, neurodevelopmental disorders, epilepsy, rare diseases, and exome. Our 58,000 square foot “SuperLab” is CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified. We have conducted more than 1.5 million genetic tests to date (excluding COVID testing). Our flagship hereditary cancer panel, CancerNext®, includes 36 genes linked to an increased lifetime risk for one or more cancers such as breast, colorectal, ovarian, uterine and others.
Ambry has a strong history of firsts in the industry:
- first to offer full-gene sequencing of CFTR in 2001 and clinical exome sequencing services in 2011,
- first to offer BRCA-related testing following the Supreme Court ruling in 2013, and
- first to offer paired DNA/RNA genetic testing for hereditary cancer in 2019.
Ambry has over 100 genetic counselors and other medical experts with clinical genomic experience. Ambry’s translational scientists are also heavily involved in research collaborations and have over 400 peer-reviewed publications and nearly 450 studies presented at national and international conferences.
Ambry also offers the CARE (Comprehensive Assessment Risk and Education) Program™. CARE identifies patients at increased risk for diseases—earlier. Developed to provide physicians and patients with genetic insights and support, we’re making it easy to guide medical management and make personalized treatment decisions. CARE streamlines screening, provides education on genetic testing and links test ordering and results together in one online platform.
Ambry has six main company values:
- Be real. We believe our authenticity enables us to work together with trust and transparency.
- We care. We recognize that behind each sample, there is a person looking for an answer.
- We evolve. Whether it’s our products, technology, or even ourselves, Ambry believes in new and inventive ideas that advance us as a company and individuals.
- We’re motivated. Every day, we acknowledge that the work we do is meaningful and motivates us to carry forward with our best.
- One Ambry. We value the knowledge and skills of all contributors as we face down challenges and celebrate successes.
- We say, we do. We hold ourselves to a high standard and know our responsibilities.
Our embodiment of these values throughout the organization has resulted in several industry awards voted for by company employees. We were included among Orange County Top Workplaces and Comparably’s Best Company Culture, Best Company for Women, Best Company Leadership and Best Company Outlook.